DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1990)

Crohn's Disease | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) - Adult

Crohn's Disease | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) - Adult

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and maintain remission. Treatment of CD typically begins with safe, albeit often less-efficacious, conventional agents (e.g., 5-ASAs) but often progresses to more-potent drugs, such as immunosuppressants and/or biologics. However, this scenario is changing, and more physicians are prescribing biologics for recently diagnosed CD. Among the biologics, TNF-alpha inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira) are the mainstays of treatment, but newer therapies, including Takeda’s Entyvio and Janssen’s Stelara, have a growing market share.

QUESTIONS ANSWERED

  • What patient share do key therapies and brands garner by line of therapy in adult patients with newly diagnosed CD? What are the quarterly trends in prescribing among adult patients with recently treated and newly diagnosed CD?
  • How have Entyvio and Stelara been integrated into the treatment algorithm?
  • What proportion of adult CD patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of adult CD patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies? What are the product-level compliance and persistency rates among drug-treated adult patients with CD?

CONTENT HIGHLIGHTS

Geographies

United States

Real World data

Longitudinal patient-level claims data analysis

Key Drugs Covered

Humira, Remicade, Entyvio, Stelara, Cimzia, aminosalicylates, immunosuppressants

Key Analysis provided 

  • Brand/therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flowcharts

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) - Adult
    • Treatment Algorithms: Claims Data Analysis-Crohn's Disease Adult-US PPT [January 2019]

Already a Client? Log in to access this report.

  • Pub Date: January 2019
  • Author(s): Ritesh Gupta, PhD
  • Ritesh Gupta is a Lead Analyst on the immune and inflammatory disorders team at Decision Resources Group, whose work focuses primarily on Psoriatic Arthritis, Ulcerative Colitis and Crohn’s Disease. He holds a degree in Cell Biology from Max Delbrück Center for Molecular Medicine, Berlin, where he worked on development of novel inhibitors for HGF/MET signaling pathways. Prior to joining DRG, Ritesh has worked as an assistant manager with BioXcel corporation and provided insights on various consulting projects. He was also associated with GVK Biosciences and worked on drug repurposing projects.

Purchase Report

Recent reports:
You may also be interested in: